Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
ExpreS2ion Biotech är ett bioteknikbolag med fokus på vacciner. Bolagets mål att bidra till hälso- och sjukvården genom att utveckla vacciner för att stödja sjukdomsförebyggande och förbättra livskvaliteten globalt. ExpreS2ion använder sin ExpreS2™-teknologiplattform, som har validerats i kliniska fas III-studier, för utveckling och produktion av vaccinkomponenter. Bland pågående projekt utvecklar bolaget ES2B-C001, ett HER2-cVLP bröstcancervaccin som genomgår kliniska fas I-prövningar.
I samband med Q2 2026-rapporten har vi uppdaterat vårt investerings-case och justerat vår värderingsmodell för den rapporterade kassan för Q2 samt den reviderade tidsplanen för Fas II.
Yesterday, ExpreS2ion Biotechnologies' management presented the financial results for Q2 2026, provided further insights into the recent pipeline developments with focus on the breast cancer candidate. The session was followed by an Q&A
ExpreS2ion is expected to release its H1 2026 interim report on 20 August 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
ExpreS2ion has today announced the outcome of the third scheduled DSMB meeting in the Phase I trial of ES2B C001, alongside expanded preliminary immunogenicity and safety data.
In connection with the Q1 2026 report, we have updated our investment case.
Q1 2026 has moved ExpreS2ion meaningfully forward and further derisked the investment case, with continued positive ES2B-C001 read-outs, a redesigned and strengthened Phase I programme, and a completed rights issue potentially securing the company's path to the end-2026 Phase I read-out.
Today, ExpreS2ion Biotechnologies' management presented the financial results for Q1 2026, provided further insights into the recent pipeline developments with focus on the breast cancer, malaria and Nipah candidates, and shared the latest updates on the completed rights issue and the partnering outlook for ES2B-C001.
ExpreS2ion is expected to release its Q1 2026 interim report on 28 May 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
